Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Neil Canavan
Medical Writer
Medical Writer
Authored Items
Rehospitalization Is Driving Costs in Pulmonary Arterial Hypertension
Neil Canavan
November/December 2013, Vol 6, No 9
in
Industry Trends
First Cost Analysis of Long-Term Management of CML
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Bosutinib Shows Superior Results in CML
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
in
Leukemia
Ready-Made Platelets? A Boon for Patients If It Works
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
in
Conference Highlights ASH
Cost of Treating Myeloproliferative Neoplasms Is Significant
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Investigational Blinatumomab Puts BiTE on Acute Lymphoblastic Leukemia
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
in
Leukemia
Hematologists Are Told to Get Ready for ACOs
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Chronic Myeloid Leukemia: Are We Close to Finding a Cure?
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
Favorable Data for Ruxolitinib and for a New JAK Inhibitor in Myelofibrosis
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
in
Conference Highlights ASH
DVT Prophylaxis: First Comparison of Catheter- Directed Thrombolysis versus Standard Care
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
in
Conference Highlights ASH
Ponatinib Overcomes Hard-to-Treat T315I Mutation in Patients with CML/ALL
Neil Canavan
,
Neil Canavan
February 2012 Vol 5, No 1, Special Issue
in
Leukemia
Last modified: December 19, 2013